← Leaderboards
George A O'Doherty
West Virginia University
$4,408,102
Attributed
$7,049,011
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,049,011 · 8
By mechanism
R01$5,910,424 · 4
R21$951,603 · 2
R03$182,984 · 1
R13$4,000 · 1
Top collaborators
- James E Kirby10 shared
- Edward W Yu4 shared
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogPharmaceutical ChemistryLaboratoriesBaseInfectionMulti-Drug ResistanceCarbohydratesSchemeAnti-Infective AgentsModificationStructureAntimicrobialPositioning AttributeSugarFrequenciesPathogenic BacteriaMicrobiologyAcinetobacter BaumanniiEnzymesAntibioticsPseudomonas AeruginosaEmerging Antimicrobial ResistanceCarbapenem-Resistant EnterobacteriaceaePathogen
Grant awards (23)
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity$757,156
R01 · FY2023 · AI
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity$765,318
R01 · FY2022 · AI
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity$772,551
R01 · FY2021 · AI
De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity$815,399
R01 · FY2020 · AI
Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogens$210,119
R21 · FY2020 · AI
Fusidic acid derivatization to enhance entry into Gram-negative pathogens$209,030
R21 · FY2020 · AI
Targeted modification of the apramycin 2-deoxystreptamine ring to block aminoglycoside modifying enzyme-based inactivation and enhance potency against multidrug-resistant Gram-negative pathogens$82,117
R03 · FY2020 · AI
Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogens$266,324
R21 · FY2019 · AI
Fusidic acid derivatization to enhance entry into Gram-negative pathogens$266,130
R21 · FY2019 · AI
Targeted modification of the apramycin 2-deoxystreptamine ring to block aminoglycoside modifying enzyme-based inactivation and enhance potency against multidrug-resistant Gram-negative pathogens$100,867
R03 · FY2019 · AI
2013 Carbohydrate GRC$4,000
R13 · FY2013 · GM · contact PI
De Novo Synthesis of Oligosaccharides$304,811
R01 · FY2012 · GM · contact PI
De Novo Synthesis of Oligosaccharides$304,811
R01 · FY2011 · GM · contact PI
De Novo Synthesis of Oligosaccharides$307,890
R01 · FY2010 · GM · contact PI
De Novo Synthesis for MedChem on Sugars$307,546
R01 · FY2010 · GM · contact PI
De Novo Synthesis for MedChem on Sugars$3,254
R01 · FY2010 · GM · contact PI
De Novo Synthesis of Oligosaccharides$293,000
R01 · FY2009 · GM · contact PI
De Novo Synthesis for MedChem on Sugars$293,000
R01 · FY2009 · GM · contact PI
Synthesis of Papulacandins A-D;New Antifungal Analogs$248,200
R01 · FY2005 · GM
Synthesis of Papulacandins A-D;New Antifungal Analogs$248,200
R01 · FY2004 · GM
Synthesis of Papulacandins A-D;New Antifungal Analogs$248,200
R01 · FY2003 · GM
Synthesis of Papulacandins A-D;New Antifungal Analogs$149,619
R01 · FY2002 · GM
Synthesis of Papulacandins A-D;New Antifungal Analogs$91,469
R01 · FY2002 · GM